Direkt zum Inhalt
Merck
  • Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure.

Hydroxyhydroquinone-free coffee: a double-blind, randomized controlled dose-response study of blood pressure.

Nutrition, metabolism, and cardiovascular diseases : NMCD (2007-10-24)
Tohru Yamaguchi, Akiro Chikama, Kenta Mori, Takuya Watanabe, Yasushi Shioya, Yoshihisa Katsuragi, Ichiro Tokimitsu
ZUSAMMENFASSUNG

Coffee is rich in chlorogenic acids (CGA), whose metabolites may have beneficial effects such as anti-hypertensive effects. However, trial results concerning the effects of coffee on blood pressure (BP) are not consistent. A recent study suggested that hydroxyhydroquinone (HHQ), produced by the roasting of green coffee beans, inhibits the effect of CGA. In the present study, the dose-response for CGA in HHQ-free coffee on BP were investigated in mildly hypertensive men and women. The trial design was a double-blind, randomized controlled trial, with five study groups including, control, zero-dose, low-dose, middle-dose and high-dose. The control beverage was identical to ordinary coffee. The others contained reduced HHQ levels, compared to ordinary coffee, and the CGA were adjusted in target concentration. A total of 203 subjects were randomly allocated. Each subject drank one cup of coffee per day. The study involved a screening and a baseline observation period of 6 weeks and an intervention period of 4 weeks. BP response showed CGA has an anti-hypertensive effect in a dose-dependent manner in HHQ-free coffee, and ordinary coffee showed almost no effect. As a result, a significant correlation between BP change and the three dose-response patterns was observed (p<0.001). This study demonstrates a dose-dependent decrease in BP for CGA in HHQ-free coffee.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
1,2,4-Benzoltriol, ReagentPlus®, 99%